Page last updated: 2024-09-02

ecteinascidin 743 and Epithelial Neoplasms

ecteinascidin 743 has been researched along with Epithelial Neoplasms in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bonetti, A; Giuliani, J1
C Cecere, S; Du Bois, A; Harter, P; Heitz, F; Pignata, S1
Bazaeva, IIa; Cherkasova, MV; Gorbunova, VA; Khokhlova, SV; Limareva, SV; Orel, NF1
López-Guerrero, JA; Poveda, A; Romero, I1
Herzog, TJ; Teplinsky, E1
Herzog, TJ; Kaye, SB; Krasner, CN; Monk, BJ; Muggia, FM; Parekh, TV; Park, YC; Poveda, AM; Pujade-Lauraine, E; Vermorken, JB1

Reviews

4 review(s) available for ecteinascidin 743 and Epithelial Neoplasms

ArticleYear
Treatment of recurrent ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Nov-01, Volume: 28, Issue:suppl_8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Tetrahydroisoquinolines; Trabectedin

2017
[Which patients with ovarian cancer shows the combination of trabectedin with pegylated liposomal doxorubicin].
    Vestnik Rossiiskoi akademii meditsinskikh nauk, 2013, Issue:11

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Carcinoma, Ovarian Epithelial; Dioxoles; Doxorubicin; Drug Therapy, Combination; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Patient Selection; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome

2013
Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.
    Chinese journal of cancer, 2015, Volume: 34, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Dioxoles; DNA Damage; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment

2015
The efficacy of trabectedin in treating ovarian cancer.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Discovery; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment

2017

Trials

1 trial(s) available for ecteinascidin 743 and Epithelial Neoplasms

ArticleYear
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:15

    Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Survival Analysis; Tetrahydroisoquinolines; Trabectedin

2012

Other Studies

1 other study(ies) available for ecteinascidin 743 and Epithelial Neoplasms

ArticleYear
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Costs; European Union; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines; Trabectedin

2017